Vir Biotechnology
E446849
Vir Biotechnology is a clinical-stage immunology company focused on developing treatments and prophylactics for serious infectious diseases using antibody, T cell, and other immune-based technologies.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Vir Biotechnology canonical | 3 |
How this entity was disambiguated
This entity first appeared as the object of triple T4492426 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Vir Biotechnology Context triple: [Alnylam Pharmaceuticals, collaboratesWith, Vir Biotechnology]
-
A.
BioNTech
BioNTech is a German biotechnology company best known for developing one of the first mRNA-based COVID-19 vaccines in partnership with Pfizer.
-
B.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
C.
Verily Life Sciences LLC
Verily Life Sciences LLC is a health-focused research and technology company that develops tools and platforms to collect, organize, and analyze health data, particularly in areas like clinical research, precision health, and disease management.
-
D.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
E.
Janssen Biotech
Janssen Biotech is a biopharmaceutical company known for developing and manufacturing innovative biologic therapies, including the blockbuster monoclonal antibody Remicade.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Vir Biotechnology Target entity description: Vir Biotechnology is a clinical-stage immunology company focused on developing treatments and prophylactics for serious infectious diseases using antibody, T cell, and other immune-based technologies.
-
A.
BioNTech
BioNTech is a German biotechnology company best known for developing one of the first mRNA-based COVID-19 vaccines in partnership with Pfizer.
-
B.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
C.
Verily Life Sciences LLC
Verily Life Sciences LLC is a health-focused research and technology company that develops tools and platforms to collect, organize, and analyze health data, particularly in areas like clinical research, precision health, and disease management.
-
D.
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a leading American biotechnology company known for developing innovative antibody-based therapies for serious diseases, including eye disorders, cancer, and inflammatory conditions.
-
E.
Janssen Biotech
Janssen Biotech is a biopharmaceutical company known for developing and manufacturing innovative biologic therapies, including the blockbuster monoclonal antibody Remicade.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
clinical-stage biopharmaceutical company ⓘ immunology company ⓘ |
| aimsTo |
address global public health threats
ⓘ
prevent infectious diseases ⓘ treat infectious diseases ⓘ |
| collaboratesWith |
GlaxoSmithKline
ⓘ
governmental health agencies ⓘ non-profit organizations ⓘ |
| country |
United States
ⓘ
linked to:
United States of America
|
| develops |
T cell–based therapies
ⓘ
immune-based therapies ⓘ monoclonal antibodies ⓘ prophylactics ⓘ therapeutics ⓘ |
| employs |
T cell engineering
ⓘ
antibody discovery platforms ⓘ immune modulation strategies ⓘ |
| focusesOn |
immunology
ⓘ
infectious diseases ⓘ serious infectious diseases ⓘ |
| goal |
achieve durable immune responses
ⓘ
reduce disease burden from infectious diseases ⓘ |
| hasApproach |
functional genomics
ⓘ
harnessing the immune system ⓘ machine learning–driven target identification ⓘ |
| hasPipeline |
T cell–based candidates
ⓘ
monoclonal antibody candidates ⓘ vaccinal approaches ⓘ |
| hasResearchArea |
COVID-19
ⓘ
linked to:
COVID-19 pandemic
HIV ⓘ
linked to:
HIV-1
SARS-CoV-2 ⓘ hepatitis B virus ⓘ influenza ⓘ malaria ⓘ tuberculosis ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| stage | clinical-stage ⓘ |
| targets |
bacterial pathogens
ⓘ
parasitic pathogens ⓘ viral pathogens ⓘ |
| therapeuticArea |
chronic viral infections
ⓘ
emerging infectious diseases ⓘ respiratory viral infections ⓘ |
| usesTechnology |
T cell technology
ⓘ
antibody technology ⓘ immune-based technology platforms ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Vir Biotechnology Description of subject: Vir Biotechnology is a clinical-stage immunology company focused on developing treatments and prophylactics for serious infectious diseases using antibody, T cell, and other immune-based technologies.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.